Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 566 participants.

Also called NCT01306214

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 566 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01306214
  • EudraCT 2010-019968-37
Other papers using this trial's data
  • Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes Diabetes care, 2014-07 DOI, PubMed 24929430

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Bulgaria, Colombia, Czechia, Finland, France, Germany, Guatemala, Mexico, Peru, Russia, Spain, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01306214. Randomized; double masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2014-06-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Condition
Obesity
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
BI 10773
Intervention (Drug)
BI 10773
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01306214
Content hash
e5c91d60985075579957f0920baff5bcd0b238e46b30186c3b71936e0e427d39